5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation.

Abstract

AMP-activated protein kinase (AMPK) controls glucose uptake and glycolysis in muscle. Little is known about its role in liver glucose uptake, which is controlled by glucokinase. We report here that 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR), metformin, and oligomycin activated AMPK and inhibited glucose phosphorylation and glycolysis in… (More)

Topics

Cite this paper

@article{Guigas20065Aminoimidazole4carboxamide1betaDri, title={5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation.}, author={Bruno Guigas and Luc Bertrand and Nellie Taleux and Marc Foretz and Nicolas F Wiernsperger and Didier Vertommen and Fabrizio Andreelli and Benoit Viollet and Louis Hue}, journal={Diabetes}, year={2006}, volume={55 4}, pages={865-74} }